Valuation : Xspray Pharma AB

Market Cap 459M 47.32M 40.77M 38.61M 34.99M 65.65M 4.52B 65.98M 176M 2.3B 178M 174M 7.27B P/E 2026 *
-1.56x
P/E 2027 * 2.93x
Enterprise Value 459M 47.32M 40.77M 38.61M 34.99M 65.65M 4.52B 65.98M 176M 2.3B 178M 174M 7.27B EV / Sales 2026 *
23.8x
EV / Sales 2027 * 0.81x
Free-Float
77.26%
Yield 2026 *
-
Yield 2027 * -
1 day+1.26%
1 week-4.07%
Current month-3.69%
1 month-29.93%
3 months-33.31%
6 months-63.44%
Current year-69.25%
1 week 9.55
Extreme 9.55
10.14
1 month 9.55
Extreme 9.55
14.4
Current year 9.55
Extreme 9.55
32.5
1 year 9.55
Extreme 9.55
64.1
3 years 9.55
Extreme 9.55
91.7
5 years 9.55
Extreme 9.55
138.9
10 years 9.55
Extreme 9.55
267
Manager TitleAgeSince
Chief Executive Officer - 2026-05-31
Director of Finance/CFO 34 -
Chief Tech/Sci/R&D Officer 73 2022-12-31
Director TitleAgeSince
Director/Board Member 70 2014-12-31
Director/Board Member 52 2018-12-31
Chairman 72 2022-05-18
Date Insider Type Main position Quantity % Market Cap. Importance
8/20/26 Buy

Director

3,690 0.0078%
6/3/26 Sell

Director

-19,999 0.0422%
6/3/26 Buy

Director

26,620 0.0561%
Change 5-day change 1-year change 3-year change Capi.($)
+1.26%-4.07%-80.20%-78.02% 47.32M
-2.11%-1.68%+44.52%+95.15% 66.93B
-0.23%-4.45%+30.39%+73.64% 61.97B
+1.67%+2.47%-11.23%+388.34% 28.27B
-1.05%-4.43%+30.56%+10.07% 24.59B
+0.34%-6.78%-7.27%-17.99% 24.3B
+0.43%-3.37%+14.85%-19.29% 19.41B
-3.03%-2.29%+185.12%+334.07% 16.77B
-1.94%-4.94%-5.29%+495.65% 14.18B
-2.28%-4.90%+43.64%+155.21% 13.91B
Average -0.69%-3.52%+24.51%+143.68% 27.04B
Weighted average by Cap. -0.84%-3.06%+33.44%+133.63%

Financials

2026 *2027 *
Net sales 19.3M 1.99M 1.72M 1.63M 1.47M 2.76M 190M 2.78M 7.42M 96.81M 7.48M 7.32M 306M 564M 58.21M 50.15M 47.49M 43.04M 80.75M 5.56B 81.16M 217M 2.83B 219M 214M 8.94B
Net income - -
Net Debt - -
Logo Xspray Pharma AB
XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments. The product candidates include Sprycel, also known as HyNap-Dasa, (version of dasatinib medicine), Tasigna, also under name HyNap-Nilo, (version of nilotinib medicine) and Nexavar, also is under name HyNap-Sora, (version of sorafenib medicine), among others. Sprycel and Tasigna are indicated for treatment of adult patients diagnosed with Philadelphia chromosome-positive (pH+) chronic myeloid leukemia (CML). Sprycel is also indicated for the treatment of adult patients with pH+ acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. Nexavar is indicated for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.
Employees
24
Date Price Change Volume
26-09-11 SEK 9.670 +1.26% 25,412
26-09-10 SEK 9.550 -3.14% 86,633
26-09-09 SEK 9.860 -1.60% 43,685
26-09-08 SEK 10.02 0.00% 14,728
26-09-07 SEK 10.02 -0.60% 39,288

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XSPRAY Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!